SynthesisAdvances in rheumatology (London, England)2020
Severe COVID-19: what have we learned with the immunopathogenesis?
Synthesis in Advances in rheumatology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adaptive immunity to SARS-CoV-2 infection: A systematic review.Frontiers in immunology · 2022Pooled it
- Multiorgan Molecular Landscape of Severe COVID-19 Revealed by Consensus Gene Signatures and RAB8B Targeting.Journal of medical virology · 2026Article
- An Analysis Between Body Composition and Vertigo Post-Coronavirus Disease 2019 Patients.International archives of otorhinolaryngology · 2025Article
- Predicting coronavirus disease 2019 severity using explainable artificial intelligence techniques.Scientific reports · 2025Article
- SARS-CoV-2 Infections in a Triad of Primary School Learners (Grades 1-7), Their Parents, and Teachers in KwaZulu-Natal, South Africa: Protocol for a Cross-Sectional and Nested Case-Cohort Study.JMIR research protocols · 2024Article
- Predictors of interferon-gamma release assay results and their association with COVID-19 infection outcomes.IJTLD open · 2024Article
- Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects.Molecules (Basel, Switzerland) · 2024Review
- Meeting the Challenge of Controlling Viral Immunopathology.International journal of molecular sciences · 2024Review
- Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review.Annals of medicine and surgery (2012) · 2024Review
- HLA-B27 did not protect against COVID-19 in patients with axial spondyloarthritis - data from the ReumaCov-Brasil Registry.Advances in rheumatology (London, England) · 2023Article
- Association between the severity of periodontitis, COVID-19, C-reactive protein and interleukin-6 levels in hospitalized patients: a case‒control study.BMC oral health · 2023Article
- Hematologic tests and their association with the severity of COVID-19 and periodontitis in hospitalized patients: a case-control study.BMC oral health · 2023Article
- Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome.Clinical and experimental medicine · 2023Review
- Human inherited complete STAT2 deficiency underlies inflammatory viral diseases.The Journal of clinical investigation · 2023Article
- Review
- Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal COVID-19 cases.Immunology · 2023Article
- Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children.The Journal of allergy and clinical immunology · 2023Review
- The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups.Pathogens (Basel, Switzerland) · 2023Review
- Policies on children and schools during the SARS-CoV-2 pandemic in Western Europe.Frontiers in public health · 2023Review
- Acute kidney injury associated to COVID-19 leads to a strong unbalance of circulant immune mediators.Cytokine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global major concern. In this review, we addressed a theoretical model on immunopathogenesis associated with severe COVID-19, based on the current literature of SARS-CoV-2 and other epidemic pathogenic coronaviruses, such as SARS and MERS. Several studies have suggested that immune dysregulation and hyperinflammatory response induced by SARS-CoV-2 are more involved in disease severity than the virus itself.Immune dysregulation due to COVID-19 is characterized by delayed and impaired interferon response, lymphocyte exhaustion and cytokine storm that ultimately lead to diffuse lung tissue damage and posterior thrombotic phenomena.Considering there is a lack of clinical evidence provided by randomized clinical trials, the knowledge about SARS-CoV-2 disease pathogenesis and immune response is a cornerstone to develop rationale-based clinical therapeutic strategies. In this narrative review, the authors aimed to describe the immunopathogenesis of severe forms of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.